The abstract is read at the publisher; the summary is JClub's.
ASSURE-ID, a Delphi-consensus tool for observational infectious-disease treatment studies, was applied to 14 bloodstream-infection studies on carbapenem-resistant Enterobacterales and revealed major reporting gaps.
- Why it matters: Observational studies often inform treatment recommendations when trials are unavailable, but weak rigor can undermine validity and reproducibility. A standardized way to assess quality and bias is needed.
- What they did: ASSURE-ID was developed with 34 international experts over three Delphi rounds into five domains, 42 items, and 48 assessment questions. It was piloted and then applied after screening 5268 records, using a PROSPERO-registered review (CRD420251065957).
- The result: Only 7% of included studies reported protocol pre-registration, 14% reported adherence to official reporting guidelines, and none reported a pre-established statistical analysis plan; causal models were rare (29%). The tool provides a structured framework and shows substantial limitations in this evidence base.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.